Abstract
Scabies is a globally prevalent parasitic skin infestation characterized by severe pruritus and a heterogeneous clinical picture depending on the immune status of the individual. Epidemiologic studies reveal a higher susceptibility for young, old and, in general, immunocompromised individuals. Disease-related morbidity and secondary complications due to a disrupted epidermal barrier, e.g. subsequent bacterial infections and chronic kidney disease, further add to the patients´ burden1 . With current treatment options, induction of remission is achieved in most of the patients. Specifically, the oral administration of ivermectin has substantially decreased the prevalence of scabies in communities and has proven to be effective and tolerable2,3 .
| Original language | English |
|---|---|
| Journal | Journal of the European Academy of Dermatology and Venereology : JEADV |
| Volume | 34 |
| Issue number | 11 |
| Pages (from-to) | e736-e737 |
| ISSN | 0926-9959 |
| DOIs | |
| Publication status | Published - 11.2020 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Effectiveness and adverse events of ivermectin treatment for scabies in 30 infant patients: Report from a German single center'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver